Phase 1/2 Study TROP2 CAREngineered Cord Blood-Derived NK Cells + Belzutifan In Pancreatic Cancer

Part of paid clinical trials in Houston, Texas.

Sponsor
M.D. Anderson Cancer Center
Study ID
NCT07377526
Phase
PHASE1/PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • TGFBR2 KO CAR27/IL-15 NK cells — DRUG
    Given by mouth

Study Details

This is a Phase I/II study evaluating the intraperitoneal delivery of TROP2 CAR/IL-15 TGFBR2 KO NK cells in combination with oral belzutifan (120 mg daily) for patients with recurrent, locally advanced, unresectable and metastatic pancreatic cancer. The primary objectives are to assess safety and determine the recommended Phase II dose (RP2D).

Key Dates

Start date
May 26, 2026
Status verified
Jun 2026
Primary completion
Mar 1, 2028
Completion
Mar 1, 2030

Study Design

Enrollment
37 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Treatment with TROP2 CAR/IL-15 TGFBR2 KO NK cells + Oral Belzutifan
    Treatment will be administered on an inpatient basis for lymphodepleting therapy, cell infusion and first doses of belzultifan, and on an outpatient basis after patients are dismissed from the hospital and continue self-administering belzultifan at home.

Primary Outcome Measure

Safety and Adverse Events (AEs) [ Time Frame: Through study completion; an average of 1 year ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
The University of Texas M. D. Anderson Cancer CenterHoustonTexas77030
Maria Morelli, MD,PHD
[email protected]
713-745-1297
Maria Morelli, MD,PHD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Houston, TX

By condition
Pancreatic cancer
By specialty
OncologyGI oncology
By research site
The University of Texas M. D. Anderson Cancer Center· Houston, TX

Related Studies